Hyperglycemia has been recognized as a severe prognostic factor for patients affected by coronary artery obstruction. So far, a direct relationship between hyperglycemia, either as admission hyperglycemia or new diagnosis of diabetes, and in?ammation has been documented. A rise in plasma interleukin-6 and TNF-a are the most validated biomarkers to support such a hypothesis. In vitro or in animal models, hyperglycemia deranges the cardiac cell elasticity and contractility while smooth muscle cells are prone to develop greater vascular rigidity. Hyperglycemia-mediated oxidative stress and sympathetic tone overactivity seem to be responsible for such negative ?ndings. Whether antidiabetic therapy by itself or combined with other anti-in?ammatory and anti-aggregating drugs may help prevent cardiovascular deaths in such patients is still debated.
In this Research Topic, we would like to address the possible role of the new anti-diabetic drugs either alone or in combination with anti-inflammatory medications and/or anti-aggregating drugs to treat the hyperglycemia-related deranging effect of cardiac activity and vascular reactivity. Indeed, it is well known that hyperglycemia might produce a significant derangement of vascular endothelium, which on the other hand is also associated with a decline in vascular and cardia performance and at cardiovascular death. So far, possible role of anti-diabetic drugs in the prevention of cardiovascular deaths should also be evaluated.
This Research Topic will highlight the new advancement in the therapeutic processes associated with a better gluco-metabolic control and reduced cardiovascular risk/s. For such reasons, the use of new antidiabetic agents such SGLT2 and long acting glucagon-like-peptide-1-receptor agonist as cardiovascular agents and potential anti-atherosclerotic drugs should be evaluated. We invite manuscripts detailing such drug actions in molecular investigations or in clinical trials. Possible physio-pathological ?ndings derived by clinical investigations or along with devices of invasive and non-invasive procedures could be also useful to complete the data collected. Review articles are also welcomed in order to provide a deep overview of such complex metabolic-cardiovascular network.
Hyperglycemia has been recognized as a severe prognostic factor for patients affected by coronary artery obstruction. So far, a direct relationship between hyperglycemia, either as admission hyperglycemia or new diagnosis of diabetes, and in?ammation has been documented. A rise in plasma interleukin-6 and TNF-a are the most validated biomarkers to support such a hypothesis. In vitro or in animal models, hyperglycemia deranges the cardiac cell elasticity and contractility while smooth muscle cells are prone to develop greater vascular rigidity. Hyperglycemia-mediated oxidative stress and sympathetic tone overactivity seem to be responsible for such negative ?ndings. Whether antidiabetic therapy by itself or combined with other anti-in?ammatory and anti-aggregating drugs may help prevent cardiovascular deaths in such patients is still debated.
In this Research Topic, we would like to address the possible role of the new anti-diabetic drugs either alone or in combination with anti-inflammatory medications and/or anti-aggregating drugs to treat the hyperglycemia-related deranging effect of cardiac activity and vascular reactivity. Indeed, it is well known that hyperglycemia might produce a significant derangement of vascular endothelium, which on the other hand is also associated with a decline in vascular and cardia performance and at cardiovascular death. So far, possible role of anti-diabetic drugs in the prevention of cardiovascular deaths should also be evaluated.
This Research Topic will highlight the new advancement in the therapeutic processes associated with a better gluco-metabolic control and reduced cardiovascular risk/s. For such reasons, the use of new antidiabetic agents such SGLT2 and long acting glucagon-like-peptide-1-receptor agonist as cardiovascular agents and potential anti-atherosclerotic drugs should be evaluated. We invite manuscripts detailing such drug actions in molecular investigations or in clinical trials. Possible physio-pathological ?ndings derived by clinical investigations or along with devices of invasive and non-invasive procedures could be also useful to complete the data collected. Review articles are also welcomed in order to provide a deep overview of such complex metabolic-cardiovascular network.
